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Key points
 Arginine vasopressin (AVP) stimulates the release of enteroendocrine L-cell derived hormones
glucagon-like peptide-1 (GLP-1) andpeptideYY (PYY) in vitro frommouse andhuman colons.
 This is mediated by the AVP receptor 1B, which is highly enriched in colonic L-cells and linked
to the elevation of L-cell calcium and cAMP concentrations.
 By means of Ussing chambers, we show that AVP reduced colonic anion secretion, although
this was blocked by a specific neuropeptide Y receptor Y1 receptor antagonist, suggesting that
L-cell-released PYY acts locally on the epithelium to modulate fluid balance.
 In human serum samples, PYY concentrations were higher in samples with raised osmolality
and copeptin (surrogate marker for AVP).
 These findings describe, for the first time, the role of L-cells in AVP regulated intestinal fluid
secretion, potentially linking together hormonal control of blood volume and blood glucose
levels, and thus adding to our understanding of the complex pathways involved in the gut
hormonal response to different stimuli.
Abstract Arginine vasopressin (AVP) regulates fluid balance and blood pressure via AVP receptor
(AVPR)2 in the kidney and AVP receptor 1A in vascular smooth muscle. Its role in intestinal
function has received less attention. We hypothesized that enteroendocrine L-cells producing
glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) may be a target of AVP and contribute
to the control of fluid balance. Avpr1b expression was assessed by quantitative RT-PCR on
flourescence-activated cell sorting-isolated L- and control cells and was enriched in colonic
L-cells. AVP stimulatedGLP-1 andPYY release fromprimary culturedmurine and human colonic
cells and was associated with elevated calcium and cAMP concentrations in L-cells as measured
in cultures from GLU-Cre/ROSA26-GCaMP3 and GLU-Epac2camps mice. An antagonist of
AVPR1B reduced AVP-triggered hormone secretion from murine and human cells. In Ussing
chambers, basolaterally appliedAVPreduced colonic anion secretionand this effectwasblockedby
a specific neuropeptide Y receptor Y1 (NPY1R) antagonist. In human serum, PYY concentrations
were higher in samples with raised osmolality or copeptin (a surrogate marker for AVP). In
conclusion, we propose that AVP activates L-cell AVPR1B, causing GLP-1 and PYY secretion.
PYY in turn reduces colonic anion secretion via epithelial NPY1R. Our data suggest L-cells are
active players in the hypothalamic control of intestinal fluid homeostasis, providing a potential
link between the regulation of blood volume/pressure/osmolality and blood glucose.
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Introduction
The regulation of fluid balance is vital for human
health and is under the control of a number
of hormones, including arginine vasopressin (AVP;
anti-diuretic hormone). AVP is produced in the supra-
optic and paraventricular nuclei in the hypothalamus and
travels along the neuronal axons to the posterior pituitary
gland where it is released into the bloodstream. Hypo-
tension and hyperosmolarity stimulate AVP release, such
as might occur during dehydration or fluid loss. AVP can
bind to three subtypes of G-protein coupled AVP receptor
(AVPR), namely AVPR1A, AVPR1B andAVPR2, which are
differently expressed in various tissues, exerting a variety
of actions (Koshimizu et al. 2012). AVP acts upon the
kidney via AVPR2 to increase thewater permeability of the
collecting ducts, thereby promoting water reabsorption
and facilitating the production of concentrated urine.
AVP acts upon smooth muscle via AVPR1A to increase
peripheral vascular resistance and raise blood pressure
during hypovolaemic shock. Vasopressin-induced platelet
aggregation also appears to be mediated via AVPR1A
(Launay et al. 1987). The role of the AVPR1B is less
clear, although it appears to be present in the pituitary
and adrenal medulla and promotes the release of adreno-
corticotrophic hormone and catecholamines, respectively.
Another potential site of action for AVP might be the
gastrointestinal tract, which is the main route of water
entry into the body and an important site of fluid loss in
pathological states characterizedby vomitingordiarrhoea.
Intestinal water balance is known to be hormonally
regulated. Both glucocorticoids and mineralocorticoids
stimulate intestinal sodium and water absorption, with
mineralocorticoids predominantly affecting the distal part
of the colon, whereas glucocorticoids act along the length
of both the small and large bowel (Levitan & Ingelfinger,
1965; Charney et al. 1975; Binder et al. 1989; Turnamian&
Binder, 1989). Human and rodent intestine both express
vasopressin receptors (Monstein et al. 2008; Ferrier et al.
2010). The effect of AVP on intestinal water and salt
balance has been investigated previously. In vitro, AVP
increased colonic sodium, chloride and water absorption
at the same time as decreasing anion secretion (Grady
et al. 1970; Bridges et al. 1983; Bridges et al. 1984;
Knobloch et al. 1989; Vicentini-Paulino, 1992). The role
of AVP in altering intestinal water balance was also
supported by its ability to increase the pericryptal sodium
concentration and upregulate aquaporin-2 expression in
the rat distal colon (Cristia` et al. 2007). However, the
exact mechanism of intestinal AVP action has never been
examined. Furthermore, a few in vivo studies failed to
confirm that AVP stimulates intestinal salt and water
absorption as observed in vitro, possibly as a result of
the effects of AVP on gastrointestinal vasculature and/or
motility (Levitan & Mauer, 1968; Dennhardt et al. 1979).
Besides being a hormonal target, the intestine also
produces multiple hormones such as gastrin, ghrelin,
cholecystokinin, glucagon-like peptide 1 (GLP-1) and
peptide YY (PYY). These hormones are secreted from
mucosal enteroendocrine cells and co-ordinate nutrient
absorption and disposal, hunger and satiety (Gribble &
Reimann, 2015). GLP-1 and PYY are secreted by L-cells,
which are found in high numbers in the distal ileum and
colon.Theyappear tobe releasedunder similar conditions;
for example, when nutrients in the gastrointestinal lumen
make contact with L-cells after a meal (Pais et al. 2016a).
Although the main role for GLP-1 appears to be the
regulation of glucose homeostasis, the clinical use of
GLP-1 receptor agonists for the treatment of type 2
diabetes has revealed their effects on heart rate and blood
pressure, probably reflecting the expression of GLP1R in
the heart, brainstem, kidney and arterial vasculature (Pyke
et al. 2014; Richards et al. 2014). PYY, besides its effects
on appetite and gastrointestinal motility, is also a strong
inhibitor of intestinal water and anion secretion (Cox,
2007a,b). In humans, PYY reduces intestinal secretion
(Playford et al. 1990) via actions on the neuropeptide Y
receptors Y1 and Y2 (NPY1R and NPY2R) (Cox, 2008).
Thus, L-cells have the potential to influence both glucose
homeostasis and intestinal water balance. The present
study aimed to investigate whether hormone secretion
from L-cells was affected by AVP release in vivo and
in vitro and the systemic consequences.
Methods
Solutions and compounds
All compounds were purchased from Sigma-Aldrich
(Poole, UK) unless otherwise stated. BIBP3226
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trifluoroacetate was purchased fromBioquote (York, UK).
SSR-149415 (SSR) was purchased from Axon Medchem
BV (Groningen, The Netherlands). The composition of
standard bath solution used in the secretion and imaging
experiments was: 4.5 mmol l−1 KCl, 138 mmol l−1
NaCl, 4.2 mmol l−1 NaHCO3, 1.2 mmol l−1 NaH2PO4,
2.6mmol l−1 CaCl2, 1.2mmol l−1 MgCl2 and 10mmol l−1
Hepes (adjusted to pH 7.4 with NaOH). For experiments
where CoCl2 was used, carbonates and phosphates were
omitted from the saline buffer and the osmolality was
compensated with additional NaCl (143 mmol l−1 total).
The composition of Ringer solution used in the
Ussing chamber experiments was: 120 mmol l−1 NaCl,
3 mmol l−1 KCl, 0.5 mmol l−1 MgCl2, 1.25 mmol l−1
CaCl2, 23 mmol l−1 NaHCO3 and 10 mmol l−1 glucose.
Ethical approval
All animal procedures were approved by the University
of Cambridge Animal Welfare and Ethical Review Body
and conformed to the Animals (Scientific Procedures)
Act 1986 Amendment Regulations (SI 2012/3039). The
work was performed under the UK Home Office Project
License 70/7824. The ethical principles under which
The Journal of Physiology operates were fully understood
and the work complies with the animal ethics checklist.
The experiments presented did not involve regulated
procedures, other than the breeding of transgenic mice,
or in vivo intervention studies. Male and female mice,
aged 3–6 months on a C57BL6 background, were housed
in individually-ventilated cages with access to water and
chow available ad libitum. Mice were killed by cervical
dislocation and the intestinal tissue was used in the
experiments.
Transgenic mice
GLU-Venus mice have been described previously
(Reimann et al. 2008). GLU-Cre mice were created using
a bacterial artificial construct, as described previously
(Parker et al. 2012), and express Cre recombinase under
the control of the proglucagon promoter. Labelling of
intestinal L-cells with a red fluorescent protein (RFP)
was achieved by crossing GLU-Cre with ROSA26tdRFP
reporter mice (Luche et al. 2007). To monitor calcium
fluctuations in L-cells, these mice were crossed with
commercially available ROSA26-GCaMP3 reporter mice
(Zariwala et al. 2012) (Jax stock 014538) to generate
L-cell specific expression of this genetically encoded Ca2+
sensor. To monitor cAMP changes in L-cells, trans-
genic mice expressing Epac2camps under the control
of the proglucagon promoter were used; the creation
of these mice has been described previously (Psichas
et al. 2016).
Primary murine colonic crypt culture
Colonic crypts were isolated and cultured as
described previously (Reimann et al. 2008). Briefly,
mice, aged 3–6 months, were killed by cervical dislocation
and the colon was excised. Luminal contents were flushed
thoroughly with phosphate-buffered saline and the
outer muscle layer was removed. Tissue was minced and
digested with collagenase type XI (0.4 mg ml−1) and
the cell suspension plated onto Matrigel (BD Bioscience,
Oxford, UK) pre-coated 24-well plates for GLP-1
secretion experiments or on 35mm glass bottomed dishes
(Mattek Corporation, Ashland, MA, USA) for calcium
and cAMP imaging.
Preparation of crypt cultures from human colons
The present study was approved by the Research Ethics
Committee under license number 09/H0308/24. Fresh
surgical specimens of human colon were obtained from
Tissue Bank at Addenbrooke’s Hospital (Cambridge, UK)
stored at 4°C and processed within hours of surgery.
The procedure was similar to that for mouse tissue, with
the exception that the tissue was digested with a higher
concentration of collagenase XI (0.5 mg ml−1) (Habib
et al. 2013).
GLP-1 and PYY secretion assays
Some 18–24 h after plating, cells were washed and
incubated with test agents made up in standard bath
solution supplemented with 0.1% BSA for 2 h at 37°C.
At the end of the incubation, supernatants were collected
and centrifuged at 400 g for 5 min and snap frozen
on dry ice. Cells were lysed with lysis buffer containing
(mmol l–1): 50 Tris-HCl, 150 NaCl, 1% IGEPAL-CA 630,
0.5% deoxycholic acid and complete EDTA-free protease
inhibitor cocktail (Roche, Burgess Hill, UK) to extract
intracellular peptides and centrifuged at 10,000 g for
10 min and snap frozen. GLP-1 and PYY were measured
using a total GLP-1 and total PYY assay (MesoScale
Discovery, Gaithersburg, MD, USA) and supernatant
concentrations were expressed as a percentage of the total
(secreted + lysate) GLP-1 or PYY content of each well.
Calcium imaging
Intracellular calcium concentrations were monitored
from colonic crypt cultures prepared from
GluCre/ROSA26-GCaMP3/ROSA26-tdRFP mice.
L-cells were identified by RFP fluorescence and changes in
intracellular calcium levels were represented by the change
in the intensity of GCaMP3 fluorescence excited at 488 nm
using a xenon arc lamp and a monochromator (Cairn
C© 2016 The Authors The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
4868 R. Pais and others J Physiol 594.17
Research, Faversham, UK). Solutions were perfused
continuously at a rate of 1 ml min−1. Fluorescence
in the presence of the test agent was normalized to the
respective mean background fluorescence of each cell,
measured before the addition and after the washout
of the test compound. Data were smoothened with a
sliding average across 20 s. Imaging was performed
using an IX71 microscope (Olympus) with a 40× oil
immersion objective and anOrcaER camera (Hamamatsu
Photonics KK, Hamamatsu, Japan). Images were acquired
at 1 Hz and analysed, after background subtraction, using
MetaFluor software (Molecular Devices, Sunnyvale, CA,
USA).
cAMP Fo¨rster resonance energy transfer
measurements
Single-cell measurements of cAMP levels were made
using intestinal cultures from transgenic mice expressing
the Fo¨rster resonance energy transfer-based sensor
Epac2-camps (Nikolaev et al. 2004) under the control
of the proglucagon promoter. Briefly, primary colonic
L-cells, continuously perfused with saline solution with
or without test reagents at a rate of 1 ml min−1,
were visualized with a 40× oil immersion objective on
an inverted microscope (Olympus IX71). Excitation at
435 nm was achieved using a xenon arc lamp coupled
to a monochromator (Cairn Research) controlled by
MetaFluor software (MolecularDevices).Cyanfluorescent
protein (CFP) emission at 470 nm and yellow fluorescent
protein (YFP) emission at 535 nm were monitored using
an Optosplit II beam splitter (Cairn Research) and an
Orca-ER digital camera (Hamamatsu Photonics KK) and
expressed as the CFP/YFP fluorescence ratio. Data were
smoothened with a sliding average across 30 s. Peak
CFP/YFP ratios were determined at baseline (30 s period
prior to test condition) and after test reagent application,
and the response to test agent was expressed relative to
baseline.
Quantitative RT-PCR
Populations of Venus-positive cells (L-cells) or
Venus-negative cells (non-L-cells) of purity >90%
were separated from the tissues of GLU-Venus mice
using a MoFlo cell sorter (Beckman Coulter, High
Wycombe, UK) as described previously (Reimann et al.
2008). RNA was extracted from FACS-sorted cells using
a microscale RNA isolation kit (Ambion, Austin, TX,
USA) and was then reverse transcribed to cDNA in
accordance with standard protocols. The appropriate
amount of first-strand cDNA template was mixed
with specific TaqMan primers (Applied Biosystems,
Foster City, CA, USA), water and PCR Master Mix
(Applied Biosystems), and a quantitative RT-PCR
was conducted using a 7900HT Fast Real-Time PCR
system (Applied Biosystems). β-actin was used as the
normalization control. The primer/probe pairs used
in the present study were: Avpr1a: Mm00444092 m1;
Avpr1b: Mm01700416 m1; and Avpr2: Mm01193534 g1
(all from Applied Biosystems). All experiments were
performed on at least three cDNAs each isolated from one
mouse (n = 3 mice).
Short circuit current (ISc) measurement
Themost distal part of the colon (1.25 cm) was cut open
longitudinally, rinsed in Ringer solution and mounted
in an Ussing chamber (EM-LVSYS-4 system with P2400
chambers and P2404 sliders; Physiologic Instruments, San
Diego, CA, USA). Only one preparation was used from
each animal. The active epithelial surface was 0.25 cm2.
Both parts of the Ussing chambers were filled with 3 ml
of Ringer solution, maintained at 37°C and continuously
bubbledwith 5%v/vCO2/ 95%v/vO2. The transepithelial
potential difference was clamped to 0 mV using a DVC
1000 amplifier (WPI, Sarasota, FL, USA) and the resulting
short circuit current was recorded via Ag-AgCl electrodes
and 3 mol l−1 KCl agarose bridges. The recordings were
collected and stored using a Digidata 1440A acquisition
system and AxoScope, version 10.4 (Molecular Devices).
The transepithelial resistance and short circuit current (Isc)
were allowed to stabilize for at least 30 min before the
application of drugs. During this period, transepithelial
resistance was assessed by measuring current changes
in response to 2 mV pulses lasting 2.5 s, applied every
100 s. After stabilization of the electrical parameters, the
drugs applied were: 5 μmol l−1 amiloride, 1 μmol l−1
BIBP3226 (BIBP) and 1 μmol l−1 AVP. A mix of forskolin
(10 μmol l−1) + IBMX (100 μmol l−1) was applied
bilaterally at the end of each experiment to confirm the
responsiveness/viability of the tissue.
Human study design
Ethical approval was obtained to measure gut hormone
concentrations inhuman serumsamples thatwere left over
after diagnostic testing was completed (REC 14/EE/1247;
1/12/2014). We selected blood samples from patients
in which osmolality assessment had been requested for
clinical reasons. Serum was collected using a separator
tube, centrifuged within 4 h and stored at 4°C prior to
analysis. Osmolality was measured using the freeze-point
depression method (Model 3320 Osmometer; Advanced
Instruments Inc., Norwood, Massachusetts, USA). Total
PYY was measured using a commercially available
sandwich immunoassay kit (MesoScale Discovery), which
measures both the 1–36 and 3–36 forms of PYY.
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The analytical range is 28–3000 pg ml−1. Inter-assay
coefficients of variationof 7.8-16.4%were obtainedwithin
the physiological range. GLP-1 was not measured because
it is not stable during prolonged storage at 4°C.To estimate
the concentration of AVP, wemeasured copeptin, which is
a cleavage product of pro-AVP released from the pituitary
gland in equimolar quantities toAVPbut hasmuch greater
stability in plasma and is easier to measure (Morgenthaler
et al. 2006; Morgenthaler, 2010). Copeptin was measured
using a sandwich immunoassay (USCN, Houston, TX,
USA), which has an analytical range of 15.6-1000 pgml−1.
We divided the samples into low/high osmolality
(osmo) (</>295mosmol kg−1: the upper limit of normal
value) and low/high copeptin (</>300 pg ml−1; sensu
Tenderenda-Banasiuk et al. 2014; Masajtis-Zagajewska
et al. 2015). The clinical characteristics of the low osmo,
high osmo, low copeptin and high copeptin groups,
respectively, were: age (median) 77, 50, 69 and 59 years;
body mass index (BMI) (median) 21.71, 28.25, 24.02 and
27.11 kg m–2; and sex (male/female) 18/14, 20/8, 21/8 and
14/12. Age was significantly higher and BMI significantly
lower in the low osmo group compared to the high osmo
group. No significant differences in age, BMI or sex were
observed between the low and high copeptin groups.
Statistical analysis
The results are expressed as the mean ± SD unless
otherwise indicated. Statistical analysis was performed
using Prism, version 5.01 (GraphPad, San Diego, CA,
USA). GLP-1 and PYY secretion data were analysed by
two-way ANOVA, using experimental run and treatment
type as variables. Secretion data were heteroscedastic and
therefore log transformed. Post hoc testing was performed
with post hoc Dunnett’s or Bonferroni tests as indicated.
Statistical significance for Ca2+ imaging data was assessed
by Student’s t test. Human serum samples that had PYY
concentrations below the limit of detection were assigned
a value of 28 pg ml−1 and the serum PYY levels were
analysed non-parametrically by the Mann–Whitney test.
P < 0.05 was considered statistically significant.
Results
Avpr1b expression is enriched in colonic L-cell
population
The expression of AVP receptors,Avpr1a (Fig. 1A),Avpr1b
(Fig. 1B) and Avpr2 (Fig. 1C) was assessed by quantitative
RT- PCR in L- and non-L-cell populations obtained by
FACS sorting of epithelial cell suspensions from the upper
and lower half of the mouse small intestine and large
intestine. Of the three AVP receptors examined, Avpr1b
was found to be highly enriched in both small intestinal
and colonic L-cells compared to control cells and was
much higher in colonic L-cell vs. small intestinal L-cell
populations (Fig. 1B).
AVP stimulates GLP-1 and PYY secretion from mouse
colonic cultures
To monitor GLP-1 and PYY secretion, primary crypt
cultures were prepared from murine colonic tissue. Cells
were stimulated for 2 h with different concentrations of
AVP (10−13 to 10−6 mol l−1) or with a positive control
that was a combination of forskolin (10 μmol l−1), IBMX
(10μmol l−1) and glucose (10mmol l−1). AVP at or above
0.1 nmol l−1 caused a significant stimulation of GLP-1
secretion, which increased from 3.5% to comprise 28% of
the total GLP-1 content with the highest concentration
used (Fig. 2A). PYY secretion from murine colonic
cultures was also assessed in response to 2 h of incubation
with AVP (10 nmol l−1) and increased from 9% to
comprise 35% of the total PYY content (Fig. 2B).
AVP elevates intracellular calcium concentrations
in colonic L-cells
To investigate the molecular mechanisms activated by
exposure of L-cells to AVP, calcium fluctuations were
monitored in primary L-cells cultured from the colon
of GLU-Cre/ROSA26-GCaMP3 mice. These mice express
the GCaMP3 protein, a genetically encoded Ca2+ sensor,
specifically in L-cells and hence allow intracellular calcium
levels to be monitored by exciting the GFP moiety
of GCaMP3. AVP at a concentration of 10 nmol l−1
caused reversible and reproducible elevations of GCaMP3
fluorescence, which is indicative of an increase in intra-
cellular calcium in colonic L-cells (Fig. 3A and B).
Intracellular calcium increase can either be caused by
release of calcium from intracellular stores or influx of
extracellular calcium via the opening of voltage-gated
calcium channels in the plasmamembrane. To distinguish
these possibilities, calcium imaging experiments were
performed in the presence of cobalt chloride (CoCl2),
a general voltage-gated calcium channel blocker that
impairs L-cell calcium responses to depolarizing stimuli
such as KCl (Pais et al. 2016b). Cytoplasmic calcium
responses to AVP were still observed in the presence of
CoCl2 (5 mmol l−1) (Fig. 3C and D), suggesting a lack
of dependence on voltage-gated calcium channels, which
is consistent with the known Gq coupled nature of the
AVPR1B.
AVP elevates intracellular cAMP concentrations
in colonic L-cells
AVPR1B has been reported to activate both Gq-inositol
phosphate and Gs-cAMP pathways, depending on
C© 2016 The Authors The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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the ligand and the localization within specialized
compartments on the plasma membrane (Orcel et al.
2009). We tested the effect of AVP on intracellular cAMP
levels in single L-cells in primary cultures prepared
from transgenic mice expressing the Fo¨rster resonance
energy transfer-based sensor Epac2-camps under the
control of the proglucagon promoter. In colonic cultures,
AVP (10 nmol l−1) treatment resulted in an acute
increase in the CFP/YFP fluorescence ratio, which is
indicative of an elevation of cytosolic cAMP in L-cells
(Fig. 4).
Antagonist of AVPR1B reduces AVP-stimulated GLP-1
and PYY secretion
To test the functional importance of AVPR1B, we
performed GLP-1 and PYY secretion experiments in the
presence of SSR (i.e. a selective vasopressin receptor
antagonist with specificity for the AVPR1B subtype)
(Serradeil-Le Gal et al. 2002; Serradeil-Le Gal et al. 2005).
In mouse colonic cultures, SSR (1 μmol l−1) significantly
reduced AVP triggered GLP-1 and PYY release by 70%
and80%, respectively (Fig. 5). SSR on its own, however,
had no effect on GLP-1 secretion (Fig. 5A).
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Figure 1. AVP receptors gene expression in L- and non-L-cell populations
Avpr1a (A), Avpr1b (B) and Avpr2 (C) expression was analysed by quantitative RT-PCR from FACS-isolated L- (black)
and non-L- (white) cells from the upper and lower small intestine (SI) and large intestine (LI) of mice and compared
with that of Actb in the same sample. A Ct value of 40 was assigned to samples where the target gene was
undetected. Data are presented as the geometric mean + upper SD of the 2Ct data (n  3 each). Comparisons
between L- and non-L-cells were assessed on non-transformed Ct data using one-way ANOVA and post hoc
Bonferroni analysis. ∗∗∗P < 0.001.
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Figure 2. AVP induced GLP-1 and PYY secretion from murine colonic cultures
A, mixed intestinal cultures generated from mouse colons were incubated for 2 h in saline solution alone (Control;
Con) or containing increasing concentrations of AVP or F/I/G, forskolin (10 μmol l−1) plus IBMX (10 μmol l−1) plus
glucose (10 mmol l−1). B, PYY secretion was measured from mixed cultures incubated with a single concentration
of AVP (10 nmol l−1). GLP-1 and PYY secretion is expressed as a percentage of total content. Results are shown
as the mean + SD of (A) n = 9 and (B) n = 13 or 14 wells with 3 or 4 wells originating from a single mouse.
∗∗∗P < 0.001 compared to controls using one-way ANOVA followed by post hoc Bonferroni analysis on log10
transformed data.
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AVP stimulates GLP-1 and PYY secretion from human
colonic cultures
To determine whether AVP has an effect on gut hormone
secretion inhumans,weused crypt cultures prepared from
fresh human colon specimens obtainedwithin a few hours
of surgery. GLP-1 and PYY concentrations weremeasured
in supernatants and cell lysates after 2 h of incubation
in the presence of 10 nmol l−1 AVP. AVP significantly
stimulated GLP-1 and PYY secretion by 2-fold and
1.5-fold, respectively (Fig. 6). As in the murine cultures,
SSR (1 μmol l−1) significantly blocked the effect of AVP
on GLP-1 release, suggesting that stimulation is mediated
via AVPR1B in humans (Fig. 6A). The reduction of PYY
release by SSR did not reach statistical significance in
human cultures (Fig. 6B).
Anti-secretory effect of AVP in the mouse colon
We employed Ussing chambers to study the functional
relevance of AVP in the mouse colon. Basolateral addition
of AVP (1μmol l−1) caused a reduction in the short circuit
current (Isc) without any obvious change in the trans-
epithelial resistance. In five of nine tissue preparations,
the Isc change followed a simple curve, reaching a plateau
several minutes after the addition of AVP (Fig. 7Aa). The
other samples showed more complicated kinetics, with
an initial drop in Isc and then a period of stabilization
or even a slight increase in Isc, followed by a second fall
(Fig. 7Ab). In all cases, Isc remained depressed for at least
20 min after AVP addition. Pre-treatment with apically
added amiloride (5 μmol l−1) caused a decrease of Isc that
sometimes partially recovered, reaching a new plateau in
0
200
400
600
800
1000
AVP AVP 1 min
48
8 
flu
or
es
ce
nc
e
Baseline 1st app. 2nd app.
0
1
2
3
4
5
AVP
***
***
R
el
at
iv
e 
48
8 
flu
or
es
ce
nc
e
0
200
400
600
800
CoCl2
CoCl2
AVP AVP 1 min
48
8 
flu
or
es
ce
nc
e
Baseline AVP
0
2
4
6
***
R
el
at
iv
e 
48
8 
flu
or
es
ce
nc
e
A B
C D
Figure 3. Intracellular Ca2+ changes in colonic L-cells in response to AVP
Mixed colonic cultures were generated from GLU-Cre/ROSA26-GCaMP3/ROSA26-tdRFP mice and L-cells were
identified by their RFP fluorescence. A, representative trace showing calcium response to AVP (10 nmol l−1) in
an L-cell as a measure of GCaMP3 fluorescence. B, mean GCaMP3 fluorescence changes in L-cells in response to
two applications of AVP in the same cell. n = 9 cells and results are the mean + SD. ∗∗∗P < 0.001 compared to
baseline by one-sample Student’s t test. C, representative trace showing calcium response to AVP (10 nmol l−1)
in the presence of cobalt chloride (CoCl2; 5 mmol l−1) to block voltage-gated calcium channels and (D) mean
calcium changes in L-cells in response to AVP (10 nmol l−1) in the presence of CoCl2 (n = 6 cells). Results are
shown as the mean + SD. ∗∗∗P < 0.001 compared to baseline by a one-sample Student’s t test.
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1–5min. Themean Isc decrease as a result of amiloride was
4.37 μA cm–2. Subsequent application of AVP, 10–12 min
after amiloride, caused a further decrease in Isc, which
was no different from the decrease caused by AVP without
any pretreatment (Fig. 7B and D). These findings suggest
that the effect of AVP was a result of the decrease in
electrogenic anion secretion and was not attributable to
an interaction with ENaC-dependent sodium absorption.
The results are in agreement with previously published
results from Ussing chamber recordings (Bridges et al.
1984; Xue et al. 2014). Pre-treatmentwith the basolaterally
added specific NPY1R antagonist BIBP caused an increase
of Isc, reaching a new plateau in 3–6 min. The mean Isc
increase as a result of BIBP was 7.84 μA cm–2. Subsequent
application of AVP, 10–12 min after BIBP, triggered
a significantly smaller drop in Isc compared to when
AVP was applied without BIBP pretreatment, confirming
a role of the PYY receptor NPY1R in AVP-mediated
changes of colonic transepithelial ion movement
(Fig. 7C and D).
Human plasma PYY levels
To assess whether PYY release is influenced by AVP in
humans, we measured PYY and copeptin concentrations
in anonymized human serum samples that had been sent
for clinical measurement of osmolality. Copeptin, similar
to AVP, is produced by post-translational processing of
pre-provasopressin, although it is more stable in stored
serum samples and can be used as an indirect measure
of AVP concentrations (Morgenthaler et al. 2006). We
hypothesized that serum PYY concentrations would be
elevated in conditions of elevated copeptin or osmolality.
Figure 8A and B shows the scatter of PYY concentrations
plotted against osmolality and copeptin. Because we do
not predict a linear effect on PYY, we divided the samples
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Figure 4. Intracellular cAMP changes in colonic L-cells in response to AVP
Mixed colonic cultures were generated from mice expressing Epac2camps in L-cells. A, representative trace of
cAMP response in an L-cell as measured by the CFP/YFP ratio in the presence of AVP (10 nmol l−1) and F/I,
forskolin (10 μmol l−1) + IBMX (100 μmol l−1). B, mean CFP/YFP changes in L-cells after the addition of AVP
(n = 24) and F/I (n = 23). Results are shown as the mean + SD. ∗∗∗P < 0.001 compared to baseline by one-sample
Student’s t test.
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Figure 5. Antagonist of AVPR1B reduces GLP-1 and PYY
secretion from murine colonic cultures
GLP-1 (A) and PYY (B) secretion was measured from cultures
treated with AVP (10 nmol l−1) in the presence or absence of
SSR (1 μmol l−1), a selective AVPR1B antagonist. Where
applicable, wells were pre-treated with SSR, 30 min before the
administration of AVP. GLP-1 and PYY secretion is expressed as
a percentage of total content. Results are shown as the
mean + SD; n = 9–17 wells with 3 or 4 wells originating from
a single mouse. ∗∗∗P < 0.001 compared to controls or as
indicated using one-way ANOVA followed by post hoc
Dunnett’s test or Bonferroni analysis on log10 transformed
data.
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into low/high osmolality (</>295 mosmol kg−1: the
upper limit of normal value) and low/high copeptin
(</>300 pgml−1; sensu Tenderenda-Banasiuk et al. 2014;
Masajtis-Zagajewska et al. 2015). PYY was significantly
higher in both the high osmolality and high copeptin
groups (Fig. 8C and D).
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Figure 6. GLP-1 and PYY secretion from human colonic cultures
Mixed intestinal cultures were generated from fresh human colonic tissues and stimulated with AVP (10 nmol l−1)
with or without the AVPR1B antagonist SSR (1 μmol l−1). As in Fig. 5, wells that were co-incubated with AVP+ SSR
received a 30 min pre-treatment with the inhibitor. GLP-1 (A) and PYY (B) secretion is expressed as a percentage
of total content. Results are shown as the mean + SD of (A) n = 10–20 wells and (B) n = 8–18 wells with 3 or
4 wells originating from a single tissue sample. ∗∗P < 0.01 and ∗∗∗P < 0.001 compared to controls or as indicated
using one-way ANOVA followed by post hoc Dunnett’s test or Bonferroni analysis on log10 transformed data.
–10
0
AVP
AVP
AVP
A a
b C
B D
AVP
AVP
5 min
10
 μ
A
5 min
10
 μ
A
5 min
10
 μ
A
5 min
10
 μ
A
Amiloride
BIBP3226
+ + +
+
+– –
––
BIBP
Amil.
–20
–30
–40 n.s.
***
Δ
Is
c 
(μ
A
/c
m
2 )
Figure 7. AVP-induced effect on short circuit current in the mouse distal colon
A, traces showing changes in short circuit current recordings (Isc) from mouse distal colon mounted in Ussing
chambers after basolateral application of AVP (1 μmol l−1). Both simple (a) and more complicated kinetics (b) are
depicted. B, Isc changes from colon tissue as in (A) but with the additional presence of apical amiloride (5 μmol l−1)
to block ENaC-dependent sodium absorption. C, Isc changes from colon tissue as in (A) but with the additional
presence of basolateral NPY1R antagonist BIBP (1 μmol l−1). D, mean changes in Isc after application of AVP alone
or in the presence of BIBP or amiloride (Amil.). Isc was calculated as the difference between the means of short
circuit currents from the 2–5 min period before and 15 min period after the application of AVP. Data are the mean
± SD from five to nine tissue preparations, normalized for a surface area of 1 cm2. ∗∗∗P < 0.001 compared to AVP
application alone using one-way ANOVA followed by post hoc Bonferroni analysis on non-transformed data.
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Discussion
In the present study, we have shown, for the first time,
that AVP stimulates GLP-1 and PYY secretion from
colonic L-cells isolated from mice and humans. It acts via
the Gq/Gs coupled receptor AVPR1B, which was found
to be highly expressed in colon and was particularly
enriched in L-cells over the neighbouring epithelial cells.
In support of this idea, a selective antagonist of AVPR1B
significantly decreased AVP-stimulated hormone release
in both mouse and human colonic cultures. Because
the action of AVP was not completely abolished by the
antagonist, however, we cannot exclude the possibility that
the alternative receptors, AVPR1A and AVPR2, also play a
role. In vitro, AVP-stimulation of L-cells raised both intra-
cellular cAMP and calcium and triggered the secretion
of both PYY and GLP-1. One of the known actions of
PYY is mediated via Y1 receptors located on neighbouring
enterocytes, reducing anion and water secretion to the
colonic lumen and ultimately altering local intestinal
water balance in the direction of water conservation. This
proposed mechanism provides an explanation for some
of the previously observed local in vitro effects of AVP
in the colon, notably a decrease in short circuit current,
a decrease in chloride secretion, and an increase in net
water and anion absorption (Bridges et al. 1983; Bridges
et al. 1984; Vicentini-Paulino, 1992; Xue et al. 2014). Given
the amount of water secreted into the gastrointestinal
tract, which is estimated to be 8 litres/24 h in humans
(Barrett & Keely, 2000), it is possible that the modulation
of intestinal secretion through this pathway could have an
impact on the systemic circulation. Indeed, I.V. infusion
of high doses of PYY to healthy volunteers increased
both diastolic and systolic blood pressure (Adrian et al.
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Figure 8. Plasma PYY measurements in human serum samples
A, scatter plot showing total PYY (pg ml–1) plotted against osmolality (mosmol kg–1) in human serum samples.
Samples were divided into low osmo and high osmo groups with a cut-off limit set at 295 mosmol kg–1 (vertical
dashed line). B, total PYY (pg ml–1) was plotted for the two groups: low osmo (circles) and high osmo (squares).
C, scatter plot showing total PYY (pg ml–1) plotted against copeptin (pg ml–1) in human serum samples. Copeptin
(cpp) was measured as a surrogate marker for AVP in the serum. Samples were divided into a low and high group
with a cut-off set at 300 pg ml−1 (vertical dashed line) and (D) total PYY (pg ml–1) was plotted for the two groups:
low cpp (circles) and high cpp (squares). Statistical comparison was made for PYY in the high and low groups by
the Mann–Whitney test. ∗P < 0.05 and ∗∗P < 0.01 for low and high groups.
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1986).Ourdata additionally suggest that serumosmolality
and AVP levels influence circulating PYY concentrations
in humans, raising the possibility of more systemic
consequences of AVP-triggered secretion from intestinal
L-cells. Age and BMIwere significantly different in the low
vs. high osmolality but not between the copeptin groups,
with the low osmo group having both a lower BMI and
lower PYY than the high osmo group. Because previous
studies reported that PYY levels are inversely related to
BMI (Batterham et al. 2003), the BMI difference probably
does not account for the difference in PYY observed in
the present study. Also, there was no influence of age
on PYY in healthy population (MacIntosh et al. 1999).
More experimentswill beneeded todeterminewhether the
described modulation of L-cells by AVP is involved in the
control of physiological hormonal blood volume/pressure
and glucose homeostasis or is solely aimed at the local
regulation of intestinal water and ionic movements.
Although it is relatively straightforward to appreciate
a possible role of AVP-induced PYY release, we can
only speculate about the purpose of the simultaneous
GLP-1 secretion. A single study has reported anionic
secretory responses of murine intestinal epithelium to
endogenously released GLP-1, as well as to application
of the GLP1R agonist exendin-4 (Joshi et al. 2013).
Other studies, however, did not report any response to
GLP-1 in guinea-pig ileum, even at high concentrations
(Baldassano et al. 2012). Similarly, we did not observe
any changes in basal short circuit current in response to
either GLP-1 or exendin-4 stimulation in preparations
from themurine distal colonmounted inUssing chambers
(data not shown). This obviously does not preclude
the possibility that GLP-1 might affect other parts of
the intestine or do so under different experimental
conditions. Inanother study,GLP-1was shownto suppress
epithelial secretory responses to electrical stimulation
of submucosal neurons (Baldassano et al. 2012). This
raises the interesting hypothesis that co-released PYY and
GLP-1 possess complementary properties with respect to
intestinal salt and water balance, inhibiting basal (PYY) as
well as neuronally stimulated (GLP-1) anion secretion.
Indeed, AVP itself was also shown to inhibit neuro-
nally stimulated secretory responses (Knobloch et al.
1989). However, we did not observe any exendin-4
related inhibition of secretory responses to electrical field
stimulation in our preparations from the mouse distal
colon (data not shown). There is also an intriguing
possibility that AVP-induced GLP-1 secretion increases
intestinal water uptake via its stimulatory effect on the
hypothalamic-pituitary-adrenal axis. Indeed, peripheral
administration of GLP-1 or exendin-4 increased levels of
both corticosterone and aldosterone in rats, whereas bolus
I.V. GLP-1 increased systemic levels of cortisol in humans
(Gil-Lozano et al. 2010; Gil-Lozano et al. 2014). Prolonged
administration of exendin-4 or other GLP-1 receptor
agonists was also associated with increased corticosterone
levels and increased water intake in rodents (Gil-Lozano
et al. 2013; Krass et al. 2015). Glucocorticoids are known
to increase intestinal sodium and water absorption from
small and large intestine as a result of their effect on
Na+/K+ ATPase, NHE3 and SGLT1 activity. Under this
mechanism, the effects of AVP-stimulated GLP-1 and
PYY secretion would also be complementary, with PYY
reducing anion andwater secretion via its direct short term
effect on enterocytes, whereas GLP-1 increases sodium
and water absorption via its longer-term modulation
of glucocorticoid levels. Of note, ablation of AVPR1B
activity by antagonists or by use of knockout animals leads
to decreased levels of glucocorticoids in the circulation,
although, here, a central direct action of AVP independent
of GLP-1 has been postulated (Koshimizu et al. 2012).
Other than its role in water retention and blood
pressure control, AVP is increasingly recognized as an
active player in the regulation of glucose homeostasis.
AVPR1B-mediated GLP-1 release from intestinal L-cells
could provide an additional level of complexity to the
direct stimulatory effect of AVP on pancreatic insulin and
glucagon secretion (Lee et al. 1995; Yibchok-Anun et al.
2000; Abu-Basha et al. 2002). For example, the elevated
AVP levels observed in uncontrolled diabetes (Vokes et al.
1987) might not only maintain fluid balance, but also
stimulate insulin secretion by promoting GLP-1 release,
thereby counteracting the hyperglycaemic state.
In summary, the data obtained in the present study
show, for the first time, the role of L-cells in AVP
regulated intestinal fluid secretion, potentially linking the
hormonal control of blood volume and blood glucose
levels. Although therapies based on GLP-1 physiology
have been highly successful in the treatment of type 2
diabetes, the alteration of intestinal salt and water balance
has recentlybeen recognizedas apromising target fornovel
drugs against hypertension, heart failure, end-stage renal
disease and chronic kidney disease (Spencer et al. 2014).
Thus, clarifying the exact role of L-cells in the cross-talk
betweenblood volume/pressure andblood glucose control
could be of potential interest with respect to our under-
standing of the range of diseases currently posing a
significant burden on modern society.
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